According to a new analysis that uses market capitalisation as a benchmark, Takeda has recently broken into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger with Shire earlier this year. According to the analysis from GlobalData, Takeda’s market cap grew to $63.4 billion in Q1 this year as
Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is
Takeda Pharmaceutical announced today that the European Medicines Agency (EMA) has agreed to review their type 2 diabetes treatment, alogliptin, a month after receiving a negative response for the therapy from the US FDA (Food and Drug Administration). The Japanese drug maker received confirmation of the acceptance of the proposal of a marketing authorisation application
Takeda Pharmaceuticals have suffered a key setback after US regulators rejected their type 2 diabetes therapy, alogliptin, and the fixed-dose combination of the medicine with Takeda’s Actos. Actos lost patent protection in 2011, and generic versions of the drug are anticipated to hit the marketplace later this year. The business received a second complete response
Takeda’s Mepact (mifamurtide) has been recommended by the National Institute for Health and Clinical Excellence (NICE) as a treatment for young patients with osteosarcoma, when it is made available to the NHS at reduced cost under a patient access scheme (PAS). In a Final Appraisal Determination (FAD) which reverses the negative FAD published by
